Skip to main content
ABCL
NASDAQ Life Sciences

AbCellera's Menopause Drug Hits Phase 2 Goals, Best-in-Class Potential

Tom Rudovsky · Reported by Reuters
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$9.433
Mkt Cap
$2.125B
52W Low
$2.745
52W High
$8.44
52W Position info
244% above low
Off High info
at 52W high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

ABCL has more than doubled off its 52-week low of $2.745.

Summary

AbCellera's ABCL635 met its primary efficacy endpoints in a Phase 2 trial for vasomotor symptoms (hot flashes) due to menopause, showing significant reductions in frequency and severity at week 4 after a single dose. The company claims best-in-class results, with additional benefits in sleep and patient-reported improvement. The drug was well-tolerated with no serious adverse events. This is the first clinical validation of AbCellera's internal pipeline, shifting the narrative from a platform company to one with a potentially valuable product. The data release follows the August 7th announcement that results were imminent, and comes amid a strong cash position bolstered by recent Jazz and Vertex collaborations. A pivotal Phase 3 program is the next major catalyst. The stock is up 32% on the good news.

At the time of this announcement, ABCL was trading at $9.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $2.75 to $8.44. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.


Price Chart

Share this article

Copied!

ABCL - Latest Insights

ABCL
Nov 09, 2026, 4:22 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $12.54
Real-time Price: $9.73 info
Change: -$2.81 (-22%) info
Market Cap: $3.165B info
ABCL
Nov 09, 2026, 4:05 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $12.90
Real-time Price: $9.73 info
Change: -$3.17 (-25%) info
Market Cap: $3.165B info
ABCL
Aug 13, 2026, 4:33 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $10.97
Real-time Price: $9.73 info
Change: -$1.24 (-11%) info
Market Cap: $3.165B info
ABCL
Aug 13, 2026, 12:05 AM EDT
Source: BusinessWire
Importance Score:
9
Price at Filing: $10.32
Real-time Price: $9.73 info
Change: -$0.590 (-6%) info
Market Cap: $3.165B info
ABCL
Aug 11, 2026, 4:59 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $9.32
Real-time Price: $9.73 info
Change: +$0.410 (+4%) info
Market Cap: $3.165B info